Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




GenVec’s TNFerade Nears NDA Status (NASDAQ:GNVC)

Michael Vlaicu (September 9th, 2009) Writes:

GenVec, Inc.

(Public, NASDAQ:GNVC)

StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus, and Herpes Simplex Virus Type 2 (HSV-2). Surrounded by cash infusions through grants, mutual and institutional investors, multi-purpose products with billion dollar market potential, and an already flowing revenue stream – GenVec is one company you shouldn’t pass by.

About

Genvec

...
Tags for this Post:
adenovector delivery, adenovector delivery technology, adenovector technology, adenovector vaccine candidate, adenovirus, Agricultural Research Service, Allergy, America, Analyst, and Lead Investment Analyst, antibodies, Antigenics Inc., Apple Inc, Associate Professor, balance disorders, bank of america corp, Barclays, Biotechnology, California, cancer, Cancer Research, Cancers, care for patients with balance disorders, ceo, Chemotherapy, clinical disease, Dendreon Corporation;, director, Douglas J. Swirsky, esophageal cancer, Executive Vice President, Executive Vice President of Research and Development, Fda, fibrosis;, Food Supply, foot-and-mouth disease, founder, Gaithersburg;, gene expression, gene therapy, GenVec Inc., Head And Neck Cancer, hearing loss;, HIV, Infectious Diseases, Laszlo Zsak, lead therapeutic product candidate, locally advanced pancreatic cancer, Major, Malaria, manager, Marvin Grubman, Maryland, meat products, Michael Vlaicu;, multi-purpose products, National Institute of Allergy, National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Naval Medical Research Center, necrosis, Oncologix Inc., Pancreatic Cancer, parasitic disease, Patrick Swazy, Paul H. Fischer, Pfizer Inc, Ph.D., Pharmaceutical, Plum Island Animal Disease Center, president and chief executive officer, Professor of Human Oncology, Q1, radiation, rectal cancer, Researchers of the Livestock Sciences, Reuters, Royce Micro, SAIC-Frederick Inc., San Francisco, second-generation vaccine candidate, Spartan Micro, stage biopharmaceutical;, Steve Jobs, Stocks to Watch, targeted radiation therapy, therapy for locally advanced pancreatic cancer, TherAtoh, TNFerade;, TNFerade™;, transcriptional start site, treatment of inoperable, treatment of locally advanced pancreatic cancer;, treatment of pancreatic cancer, treatment of various cancers;, tumor, tumors, U.S. Department of Agriculture, U.S. Food and Drug Administration, United Kingdom, United States, University of California at San Francisco, University of California Irvine Comprehensive Digestive Disease Center, University of Denver, University Of Wisconsin, USD, USDA, vaccine candidate, Vaccine Research Center, Vaccine Research Center/National Institute, Vaccines, Vice President and Chief Financial Officer, Vice President of Research and Development, Wisconsin, Yahoo, yale, Yale University School of Medicine

PennyOmega.com Stock Report! 8/04/09, ED, AGEN, ACTI, MMSI, IGT

Penny Omega (August 4th, 2009) Writes:

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

signup3m

 

Tuesday August 4, 2009

PennyOmega.com Stock Report!

**************************************************************

Consolidated Edison, Inc. (NYSE: ED) today reported second quarter earnings of $150 million or $0.55 a share compared with $552 million or $2.02 a share in 2008. Excluding items identified in the table below, earnings from ongoing operations were $131 million or $0.48 a share compared with $114 million or $0.42 a share in 2008.

Antigenics Inc. (NASDAQ: AGEN) today announced that it has entered into definitive agreements to sell in a private placement approximately 4.4 million shares of its common stock at a price of $2.28 per share, resulting in gross proceeds to the company of $10 million, before

...

PennyOmega.com Stock Report! 7/30/09, OMPI, BIOS, PCCC, PCBC, ACTU, AGEN

Penny Omega (July 30th, 2009) Writes:

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

signup3m

 

Thursday July 30, 2009

PennyOmega.com Stock Report!

**************************************************************

Today Obagi Medical Products, Inc. (Nasdaq:OMPI), the leader in topical aesthetic and therapeutic skin health systems, announced the results of a meta-analysis of 23 randomized controlled clinical trials (RCTs) that compared the company’s patented solubilized 5 percent BPO (sBPO) against existing 5 percent BPO, 1-1.2 percent clindamycin (CL) and combination BPO/CL products in reducing acne lesions. The announcement was made at the American Academy of Dermatology’s (AAD) Summer Academy Meeting in Boston, Mass. The data from the meta-analysis, using data adjusted for each study’s size, shows that this new 5 percent sBPO has an equal to superior lesion reduction profile when

...

Antigenics is a buy – Brain Tumour FDA

Michael Vlaicu (April 29th, 2009) Writes:

Antigenics, Inc.

(Public, NASDAQ:AGEN) is a buy

About: Antigenics Inc. (Antigenics), is a biotechnology company focused on developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches.

News Headlines:

Antigenics, Inc. Gets FDA Approval For Orphan Drug Designation To Oncophage For Treatment Of Glioma

Antigenics, Inc. announced that Oncophage (vitespen) has been granted orphan drug status for the treatment of glioma (brain cancer) by the US Food and Drug Administration (FDA). FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma “Glioma is such an aggressive and challenging cancer that when patients are diagnosed with recurrence of this life threatening disease, they rarely live beyond six months,” said Andrew T. Parsa, MD, PhD, associate

...

Kidney Cancer May Meet its Match with Antigenics Inc.’s (AGEN) Marketing Application Submittal

QualityStocks (October 22nd, 2008) Writes:

Renal Cell Carcinoma is the most common type of kidney cancer. According to the International Agency for Research on Cancer, renal cell carcinoma accounts for nearly 90 percent of all kidney tumors. Approximately 60,511 new cases of kidney cancer were diagnosed in 2004, 29,453 of those individuals diagnosed died from the disease.

Antigenics Inc.’s (Nasdaq: AGEN) Oncophage contains an “antigenic fingerprint” of a patient’s particular cancer. It was designed to reprogram the body’s immune system to target only the cancer cells with this specific fingerprint.

In April, 2008, Oncophage was approved in Russia for the treatment of kidney cancer patients; however, there are currently no European Medicines Agency (EMEA)-approved drug therapies in the European Union. To change this, Antigenics today announced it has submitted a Marketing Authorization Application (MAA) to the EMEA. The application is a request of approval for Antigenics’ Oncophage drug therapy for early-stage kidney cancer.

“The creation

...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.